Podium
Description
HT1
15:45 - 16:00

SIMILARITIES AND DIFFERENCES IN EUROPEAN HTA EVIDENCE REQUIREMENTS: ONE FOR ALL OR ONE FOR NONE?

Mordin M1, Fernandez MM2, Pearson I3, Copley-Merriman C1, McBride D3
1RTI Health Solutions, Ann Arbor, MI, USA, 2RTI Health Solutions, Research Triangle Park, NC, USA, 3RTI Health Solutions, Manchester, UK

To view the podium abstract visit:
View Abstract

HT2
16:00 - 16:15

A HOLISTIC APPROACH TO EVALUATE THE COST-EFFECTIVENESS OF PEMBROLIZUMAB WITH MULTIPLE INDICATIONS: A NORWAY-BASED EXAMPLE

Wu E1, Pellissier J2, Kvamme M3, Irgens K3
1Merck, North Wales, PA, USA, 2Merck & Co., Inc., North Wales, PA, USA, 3MSD Norge A/S, Drammen, Norway

To view the podium abstract visit:
View Abstract

HT3
16:15 - 16:30

USING REAL-WORLD EVIDENCE FOR HEALTH TECHNOLOGY ASSESSMENT SUBMISSIONS: LESSONS AND INSIGHTS FROM REVIEW OF NICE’S TECHNOLOGY ASSESSMENT REPORTS (2016-2017)

Aggarwal S1, Topaloglu O1, Kumar S2
1NOVEL Health Strategies, Chevy Chase, MD, USA, 2Institute for Global Policy, Washington, DC, USA

To view the podium abstract visit:
View Abstract

HT4
16:30 - 16:45

HEALTH TECHONOLGY ASSESSMENT (HTA) AGENCIES CONSIDERATION OF REAL WORLD EVIDENCE (RWE)

Jao R1, Jaksa A1, Pontynen A1, Wang X2
1Context Matters, New York, NY, USA, 2Celgene Corporation, Summit, NJ, USA

To view the podium abstract visit:
View Abstract

Tags